China Dizziness and Vertigo Cohort Study （VERIDICAL STUDY）

Condition(s) studied

Study summary

The goal of this observational study is to characterize the clinical features, etiological distribution, and longitudinal outcomes of patients with dizziness and/or vertigo in real-world neurological and otolaryngological outpatient settings across China. The main questions it aims to answer are:

What is the etiological spectrum of dizziness and vertigo in patients presenting to neurology and otolaryngology clinics in China, and how do diagnoses evolve over time under routine clinical practice? Additionally, how do symptoms, functional impairment, and treatment responses change during follow-up?

Participants presenting with dizziness and/or vertigo who are already receiving routine clinical care at participating hospitals will be enrolled in a multicenter registry. They will undergo baseline clinical assessment and complete standardized questionnaires, and will be followed at predefined intervals for up to 12 months (with possible extended follow-up) through outpatient visits, electronic diaries, or telephone interviews to assess diagnostic stability, symptom progression, and treatment outcomes in a real-world setting.

Eligibility

Primary outcome measure(s)

• Proportion of patient number with specific etiology of vestibular diseases — In every research point of follow-up, and the extended follow-up period
  For this outcome measure, we will calculate the proportion for the number of patients in each confirmed etiology of vestibular disease among the enrolled patient population or total patient count during a specific follow-up time
• Proportion of patients with moderate-to-severe vestibular symptoms improving to mild severity — In each time point to follow up within 12 months from study enrolment and during the extended follow-up phase. This proportion may be calculated for the same follow-up time period when rescue medication is administered.
  Defined as the proportion of patients from whom their moderate-to-severe vestibular symptoms improve to mild severity within the specified time window after administration of appropriate first-line acute-phase therapeutic agents selected in accordance with recommendations from disease-specific treatment guidelines.
• Reduction in days with vestibular symptoms relative to baseline vestibular symptom days — Every follow-up time point of the research
  The numeric reduction in the average number of days with vestibular symptom episodes during follow-up time point after a period of preventive treatment, compared with baseline.
• Reduction in frequence of vestibular symptom episode relative to baseline vestibular symptom frequence — Every follow-up time point of the research
  The numeric reduction in the average number of frequence with vestibular symptom episodes during follow-up time point after a period of preventive treatment, compared with baseline.
• Number of rescue-medication administrations during preventive treatment — Every follow-up time point of the research
  Number of rescue medications required for recurrent vestibular symptom episodes while on preventive medication.

Trial sites (1)

More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China

Other trials for the same condition